Beta-blockers show no benefit for heart attack patients with normal heart function

FHS
April 9, 2024
2:53 am

The REDUCE-AMI trial found that long-term beta-blocker therapy does not reduce mortality risk in acute myocardial infarction patients with preserved left ventricular ejection fraction compared to no beta-blocker treatment.

Are a high-refined carbohydrate diet and the alterations resulting from its intake linked to small intestine changes?

Researchers investigated whether a high-refined carbohydrate diet and associated metabolic alterations could cause small intestinal dysregulation.

June 27, 2023

Rocket Pharmaceuticals’ RP-A601 receives FDA designations

RP-A601 is designed to treat plakophilin-2-related arrhythmogenic cardiomyopathy (PKP2-ACM). Credit: Africa Studio via Shutterstock.com. Rocket Pharmaceuticals has received fast track and orphan drug designations for

June 9, 2023

Pα+ Psychedelic Bulletin #160: Mutual Recognition for MDMA-AT in the UK? Beckley Shares Cut of 5-MeO-DMT Data; and more – Psychedelic Alpha

Featured content in this Issue: A Look at Potential Mutual Recognition of FDA Approval for Psychedelics Via the UK MHRA’s International Recognition Procedure Beckley Psytech

March 29, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.